T2 Biosystems enters exclusive U.S. agreement with Cardinal Health

T2 Biosystems (TTOO) has entered into a multi-year exclusive U.S. agreement with Cardinal Health (CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems’ FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx Instrument, the T2Bacteria Panel, and the T2Candida Panel.